Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Literature
1.
Brusselaers N, Sadr-Azodi O, Engstrand L. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden. J Gastroenterol. 2020;55:453–61.CrossRef
2.
Lai S-W. Proton pump inhibitors and the risk of pancreatic cancer. Journal of gastroenterology. 2021:In press.
3.
Pottegård A, Broe A, Hallas J, et al. Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. Ther Adv Gastroenterol. 2016;9:671–8.CrossRef
4.
Brusselaers N, Wahlin K, Engstrand L, et al. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017;7:e017739.CrossRef
5.
Matuz M, Benkő R, Engi Z, et al. Use of proton pump inhibitors in Hungary: mixed-method study to reveal scale and characteristics. Front Pharmacol. 2020;11:552102.CrossRef
6.
Lassalle M, Le Tri T, Bardou M, et al. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol. 2020;76:449–57.CrossRef
7.
Halfdanarson OO, Pottegard A, Bjornsson ES, et al. Proton-pump inhibitors among adults: a nationwide drug-utilization study. Therap Adv Gastroenterol. 2018;11:1756284818777943.CrossRef
8.
Savarino V, Marabotto E, Zentilin P, et al. Proton pump inhibitors: use and misuse in the clinical setting. Exp Rev Clin Pharmacol. 2018;11:1123–34.CrossRef
9.
Brusselaers N, Engstrand L, Lagergren J. PPI use and oesophageal cancer: what if the results are true? Cancer Epidemiol. 2018;54:139–40.CrossRef
10.
Xie Y, Bowe B, Yan Y, et al. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ (Clinical research ed). 2019;365:l1580.
Metadata
Title
Proton pump inhibitors and the risk of pancreatic cancer
Authors
Nele Brusselaers
Omid Sadr-Azodi
Lars Engstrand
Publication date
01-03-2021
Publisher
Springer Singapore
Published in
Journal of Gastroenterology / Issue 3/2021
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-021-01761-8

Other articles of this Issue 3/2021

Journal of Gastroenterology 3/2021 Go to the issue

Original Article—Liver, Pancreas, and Biliary Tract

Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database

Review

Evidence-based clinical practice guidelines for irritable bowel syndrome 2020

Review

COVID-19-associated liver injury: from bedside to bench

Original Article—Liver, Pancreas, and Biliary Tract

Clinical outcome of conservatively managed pancreatic intraductal papillary mucinous neoplasms with mural nodules and main duct dilation

Original Article—Liver, Pancreas, and Biliary Tract

Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)

Correction

Correction to: Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits